China Medical System (867.HK; 8A8.SG) Positive Results from China Phase 3 Clinical Trial of Innovative Drug Ruxolitinib Cream with AD Indication China Medical System Holdings Limited Sep 28, 2025 16:00 JST Read More
China Medical System (867.HK; 8A8.SG) Signed Collaboration Agreements for Two Innovative Biologics Used for Passive Immunization Against Tetanus and Rabies China Medical System Holdings Limited Sep 23, 2025 13:15 JST Read More
EASD 2025 | HighTide Therapeutics Announces Oral Presentation of Phase 3 Data in Patients with Type 2 Diabetes HighTide Therapeutics Inc. Sep 17, 2025 08:00 HKT/SGT Read More
Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025 Eisai Sep 08, 2025 16:49 HKT/SGT Read More
Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025 Eisai Sep 04, 2025 09:56 HKT/SGT Read More
FDA Approves LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease Eisai Sep 01, 2025 12:44 HKT/SGT Read More
Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI(R) (lecanemab) Eisai Aug 25, 2025 18:30 HKT/SGT Read More
CMS (867.HK, 8A8.SG) Reports Growth in Revenue and Profit for H1 2025, Strategic Transformation Unlocks New Drivers China Medical System Holdings Limited Aug 19, 2025 16:00 JST Read More
UNFPA and NEC Collaborate to Build Beneficiary Information Management and e-Voucher System NEC Corporation Aug 18, 2025 13:38 HKT/SGT Read More
Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI(R) (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC Eisai Jul 31, 2025 08:30 HKT/SGT Read More
New Data Presented at AAIC Demonstrates Investigational LEQEMBI(R) (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer's Disease Eisai Jul 31, 2025 08:20 HKT/SGT Read More
Two-Year Real-World Study of LEQEMBI(R) in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025 Eisai Jul 31, 2025 08:10 HKT/SGT Read More
LENVIMA(R) (lenvatinib) in Combination with Pembrolizumab and Transarterial Chemoembolization (TACE) Approved in China for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma Eisai Jul 29, 2025 08:01 HKT/SGT Read More
China Medical System (867.HK, 8A8.SG) NDA for the Improved New Drug ZUNVEYL for Alzheimer's Disease Accepted in China China Medical System Holdings Limited Jul 29, 2025 05:00 JST Read More
Multi-Dose Diquafosol Sodium Eye Drops Obtained Approval from NMPA for Commercialisation in China Essex Bio-Technology Limited Jul 25, 2025 11:52 JST Read More
Crown Bioscience San Diego Achieves CLIA Certification to Enhance Clinical Trial Support Crown Bioscience Jul 23, 2025 09:00 HKT/SGT Read More
Hua Medicine Announces at 2025 ADA Scientific Sessions that Dorzagliatin Combined with DPP-4 Inhibitor Shows Promise in Reducing Blood Lipids While Restoring Glucose Homeostasis Hua Medicine Jun 23, 2025 12:05 HKT/SGT Read More
CanSinoBIO Launches Pneumococcal Vaccine: An Innovative Choice to Safeguard Children's Health CanSino Biologics Inc Jun 20, 2025 18:06 HKT/SGT Read More
NEC and Chugai Pharmaceutical use AI to potentially enhance cancer treatment NEC Corporation Jun 18, 2025 12:40 HKT/SGT Read More
NEC Announces Interim Results from Phase 1 Clinical Trial of NECVAX-NEO1, an AI-Driven Personalized Oral Cancer Vaccine, at ESMO Immuno-Oncology Congress 2024 NEC Corporation Dec 12, 2024 15:27 HKT/SGT Read More
